For demo purposes only – Not for redistribution
Second-line Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma
Only 35% of patients with relapsed/refractory DLBCL receive additional therapy, despite availability of multiple second-line regimens that can produce prolonged remissions. In this course, Dr. Loretta Nastoupil of MD Anderson Cancer will use patient cases to explore who is a good candidate for CAR T-cell or other second-line therapy. This course incorporates new research to effectively manage patients with relapsed or refractory DLBCL.
Learning Objectives
Upon participation in this activity, learners will be better able to:
- Summarize the latest recommendations for the second-line therapy of diffuse large B-cell lymphoma (DLBCL).
- Describe the patient and disease factors that impact the selection and sequencing of the most recent therapies for relapsed/refractory DLBCL.
Faculty
Loretta Nastoupil, MD
University of Texas MD Anderson Cancer Center Houston, TX
